Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Victor Engelhard
University of Virginia, Department: Microbiology/immun/virology
Should you be removed from our database? Contact us at [email protected]. Read more below.
PhosImmune, Inc
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Engelhard has equity in PhosImmune, which has licensed IP from UVa related to certain phosphorylated peptides identified on the surface of cancer cells. The phospholipids could be antigenic targets for the immune system and the basis for a cancer vaccine or for other diagnostic purposes.
This grant includes research to evaluate pre-existing immune responses to a large array of phospholipids in normal individuals and patients with melanoma and ovarian carcinoma. It also involves studies to evaluate, longitudinally, these responses in these cancer patients and in patients with leukemia, before and after 'standard-of-care' clinical treatment. In addition, there will be evaluation of these responses in patients with myelodysplastic syndrome, a pre-cancerous condition that progresses to acute myeloid leukemia in one to two year.
These research activities have the potential to add value to the phospholipid library presently licensed to PhosImmune and thus could alter the financial interests of PhosImmune.
Immunity to MHC-restricted phosphopeptides in healthy donors and cancer patients
In this proposal, we will characterize immunity to a new type of antigen that can focus the immune system specifically on the cancer cell. These antigens come from proteins that may regulate processes involved in malignancy. Successful completion of the work will set the stage for clinical trials of these antigens in cancer patients.
Filed on September 26, 2014.
Tell us what you know about Victor Engelhard's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Victor Engelhard filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Victor Engelhard | University of Virginia | Conflict of Interest | PhosImmune, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.